Xenetic Biosciences (Xenetic Biosciences) Total Assets : $9.39 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences Total Assets?

Xenetic Biosciences's Total Assets for the quarter that ended in Mar. 2024 was $9.39 Mil.

During the past 12 months, Xenetic Biosciences's average Total Assets Growth Rate was -8.80% per year. During the past 3 years, the average Total Assets Growth Rate was -0.60% per year. During the past 5 years, the average Total Assets Growth Rate was -37.70% per year. During the past 10 years, the average Total Assets Growth Rate was -11.90% per year.

During the past 13 years, Xenetic Biosciences's highest 3-Year average Total Assets Growth Rate was 301.70%. The lowest was -51.60%. And the median was -3.40%.

Total Assets is connected with ROA %. Xenetic Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 was -47.80%. Total Assets is also linked to Revenue through Asset Turnover. Xenetic Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 was 0.05.

Xenetic Biosciences Total Assets Historical Data

The historical data trend for Xenetic Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Total Assets Chart

Xenetic Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

21.55

13.18

19.82

14.72

10.61

Xenetic Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															13.72	12.75	11.96	10.61	9.39

Xenetic Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Xenetic Biosciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	9.796	+	0.81
	=	10.61

Xenetic Biosciences's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	8.678	+	0.716
	=	9.39

Xenetic Biosciences (NAS:XBIO) Total Assets Explanation

Total Assets is connected with ROA %.

Xenetic Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-4.78	/	( (10.605	+	9.394)	/ 2 )
	=	-4.78	/	9.9995
	=	-47.80 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Xenetic Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0.511	/	( (10.605	+	9.394)	/ 2 )
=	0.511	/	9.9995
=	0.05

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Xenetic Biosciences Total Assets Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Executives

Grigory G. Borisenko	director	40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov	director	C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow	officer: Chief Financial Officer	C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks	director	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc	10 percent owner	25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110